Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

di Patnaik, A, Weiss, G J, Papadopoulos, K P, Hofmeister, C C, Tibes, R, Tolcher, A, Isaacs, R, Jac, J, Han, M, Payumo, F C, Cotreau, M M, Ramanathan, R K
Pubblicazione 2014

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

di Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C
Pubblicato in Leukemia (2017)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

di Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J., Doss, D., Zaki, M. H., Bensmaine, A., Herring, J., Li, Y., Watkins, L., Chen, M. S., Anderson, K. C.
Pubblicato in Leukemia (2018)